India to mandate pharma plant upgrades after toxic syrup scandal
The Indian government will require all pharmaceutical manufacturers to modernize plants and upgrade testing labs following recent deaths linked to contaminated cough syrups. The Health Ministry plans to revise GMP standards, with enforcement beginning in April 2026. Firms must implement digital batch tracking, audit trails, and advanced contamination controls. Regulators aim to restore global confidence in Indian exports, which account for 20% of the world’s generic drugs supply.
neutral
1 day ago
India to mandate pharma plant upgrades after toxic syrup scandal
The Indian government will require all pharmaceutical manufacturers to modernize plants and upgrade testing labs following recent deaths linked to contaminated cough syrups. The Health Ministry plans to revise GMP standards, with enforcement beginning in April 2026. Firms must implement digital batch tracking, audit trails, and advanced contamination controls. Regulators aim to restore global confidence in Indian exports, which account for 20% of the world’s generic drugs supply.
neutral
India to mandate pharma plant upgrades after toxic syrup scandal
2 days ago
1 min read
68 words
India orders mandatory plant upgrades for drugmakers after toxic syrup deaths, tightening export safety norms.
The Indian government will require all pharmaceutical manufacturers to modernize plants and upgrade testing labs following recent deaths linked to contaminated cough syrups. The Health Ministry plans to revise GMP standards, with enforcement beginning in April 2026. Firms must implement digital batch tracking, audit trails, and advanced contamination controls. Regulators aim to restore global confidence in Indian exports, which account for 20% of the world’s generic drugs supply.
The Indian government will require all pharmaceutical manufacturers to modernize plants and upgrade testing labs following recent deaths linked to contaminated cough syrups. The Health Ministry plans to revise GMP standards, with enforcement beginning in April 2026. Firms must implement digital batch tracking, audit trails, and advanced contamination controls. Regulators aim to restore global confidence in Indian exports, which account for 20% of the world’s generic drugs supply.